Loading stock data…
Agilent Technologies, Inc. (A)
$146.85-4.01 (-2.66%)
Market ClosedLast close Sep 8
Agilent Technologies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agilent Technologies, Inc. in the Healthcare sector is trading at $146.85 with a market capitalization of $36.9B. Wall Street consensus targets $175.45 (20 analysts), implying a +19.5% move over the next 12 months. The stock is currently 10% below its 52-week high of $163.75, remaining 11.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.83B↑ | $1.80B↓ | $1.86B↑ | $1.74B↑ | $1.67B |
| Gross Profit | $990.00M↑ | $946.00M↓ | $990.00M↑ | $888.00M↑ | $866.00M |
| Operating Income | $399.00M↑ | $353.00M↓ | $443.00M↑ | $360.00M↑ | $300.00M |
| Net Income | $339.00M↑ | $305.00M↓ | $434.00M↑ | $336.00M↑ | $215.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and App...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$36.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.24
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.52%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.85%
Volume
Today's trading volume
1.60M
Recent News
Agilent (A) Upgraded to Buy: What Does It Mean for the Stock?
Agilent (A) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?
Here is how Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) and Agilent Technologies (A) have performed compared to their sector so far this year.
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.
Agilent (A) Q3 2026 Earnings Call Transcript
Pharma revenue surged 12% while advanced therapeutics grew nearly 30%, beating guidance.